Polar Capital’s Stemline Therapeutics, Inc. STML Stock Holding History

Polar Capital’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,316,106	Closed	-$6.37M	–	339
2020 Q1	$6.37M	Sell	1,316,106 -683,894	-34%	-$4.43M	0.07%	193
2019 Q4	$21.3M	Buy	2,000,000 +375,000	+23%	+$3.72M	0.19%	148
2019 Q3	$16.9M	Buy	1,625,000 +125,000	+8%	+$1.64M	0.15%	158
2019 Q2	$23M	Sell	1,500,000 -400,000	-21%	-$5.79M	0.2%	140
2019 Q1	$24.4M	Sell	1,900,000 -402,666	-17%	-$4.55M	0.23%	137
2018 Q4	$21.9M	Buy	2,302,666 +248,616	+12%	+$3.22M	0.23%	129
2018 Q3	$34.1M	Buy	2,054,050 +141,445	+7%	+$2.27M	0.29%	107
2018 Q2	$30.7K	Buy	1,912,605 +1,539,320	+412%	+$27.5M	0.18%	118
2018 Q1	$5.71M	Buy	+373,285	New	+$5.82M	0.06%	212

Polar Capital's STML Position: Q2 2020 in Review

Polar Capital sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 1,316,106 shares — an estimated $6.37M sold.

Polar Capital first reported a position in STML in Q1 2018 and held it in 9 quarters. The position peaked at $34.1M in Q3 2018. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Polar Capital reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Polar Capital sold 1,316,106 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $6.37M.
Polar Capital first reported a position in Stemline Therapeutics, Inc. in Q1 2018 and held it in 9 quarters.
Polar Capital's Stemline Therapeutics, Inc. position peaked at $34.1M in Q3 2018.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Polar Capital's 13F filing for Q2 2020, filed 14 Aug 2020.